Summit Regulatory Wednesday, November 18, 2026 +0.80 Positive

Summit Starts Phase III HARMONi-10 Trial in NSCLC

Summit Therapeutics announced the initiation of its global Phase III HARMONi-10 study evaluating ivonescimab versus durvalumab in unresectable stage III NSCLC, aiming to de-risk development. This new trial could significantly impact the company's valuation by advancing its fast-growing pipeline and competing in the lung cancer sector.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed